Pruvanserin: Difference between revisions

From Wikipedia, the free encyclopedia
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Drugbox | IUPAC_name = 7-({4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl}carbonyl)-1''H''-indole-3-carbonitrile | image = Pruvanserin...'
(No difference)

Revision as of 01:26, 30 March 2010

Pruvanserin
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 7-({4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl}carbonyl)-1H-indole-3-carbonitrile
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H21FN4O
Molar mass376.43 g/mol g·mol−1
3D model (JSmol)
  • N#Cc2c1cccc(c1nc2)C(=O)N4CCN(CCc3ccc(F)cc3)CC4

Pruvanserin (EMD-281,014, LY-2,422,347) is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly for the treatment of insomnia.[1][2] It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in Eli Lilly's development pipeline.[3][4] In addition to its sleep-enhancing properties,[5][6] pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies.[7][8][9]

See also

References

  1. ^ Bartoszyk GD, van Amsterdam C, Böttcher H, Seyfried CA (2003). "EMD 281014, a new selective serotonin 5-HT2A receptor antagonist". European Journal of Pharmacology. 473 (2–3): 229–30. PMID 12892843. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. PMID 18673166.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ "Efficacy Study of LY2422347 to Treat Insomnia - Full Text View - ClinicalTrials.gov".
  4. ^ "Eli Lilly and Company » Research Pipeline".
  5. ^ Monti JM, Jantos H (2006). "Effects of activation and blockade of 5-HT2A/2C receptors in the dorsal raphe nucleus on sleep and waking in the rat". Progress in Neuro-psychopharmacology & Biological Psychiatry. 30 (7): 1189–95. doi:10.1016/j.pnpbp.2006.02.013. PMID 16713054. {{cite journal}}: Unknown parameter |month= ignored (help)
  6. ^ Monti JM, Jantos H (2006). "Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat". European Journal of Pharmacology. 553 (1–3): 163–70. doi:10.1016/j.ejphar.2006.09.027. PMID 17059817. {{cite journal}}: Unknown parameter |month= ignored (help)
  7. ^ Patel JG, Bartoszyk GD, Edwards E, Ashby CR (2004). "The highly selective 5-hydroxytryptamine (5-HT)2A receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test". Synapse (New York, N.Y.). 52 (1): 73–5. doi:10.1002/syn.10308. PMID 14755634. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  8. ^ Adamec R, Creamer K, Bartoszyk GD, Burton P (2004). "Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats". European Journal of Pharmacology. 504 (1–2): 79–96. doi:10.1016/j.ejphar.2004.09.017. PMID 15507224. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  9. ^ Terry AV, Buccafusco JJ, Bartoszyk GD (2005). "Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys". Psychopharmacology. 179 (4): 725–32. doi:10.1007/s00213-004-2114-1. PMID 15619109. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)


Retrieved from "https://en.wikipedia.org/w/index.php?title=Pruvanserin&oldid=352863057"